Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Chubb
Daiichi Sankyo
Medtronic
Moodys
Federal Trade Commission
Express Scripts
Farmers Insurance
Teva
Deloitte

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206910

« Back to Dashboard

NDA 206910 describes JADENU, which is a drug marketed by Novartis Pharms Corp and is included in two NDAs. It is available from one supplier. There are three patents protecting this drug and three Paragraph IV challenges. Additional details are available on the JADENU profile page.

The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferasirox profile page.

Summary for 206910

Tradename:1
Applicant:1
Ingredient:1
Patents:3
Therapeutic Class:Antidotes, Deterrents, and Toxicologic Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 206910

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
JADENU deferasirox TABLET;ORAL 206910 NDA Novartis Pharmaceuticals Corporation 0078-0654 0078-0654-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0654-15)
JADENU deferasirox TABLET;ORAL 206910 NDA Novartis Pharmaceuticals Corporation 0078-0655 0078-0655-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0655-15)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength90MG
Approval Date:Mar 30, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Jan 23, 2020
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY
Patent:► SubscribePatent Expiration:Apr 5, 2019Product Flag?YSubstance Flag?YDelist Request?
Patent:► SubscribePatent Expiration:Jun 24, 2017Product Flag?Substance Flag?YDelist Request?
Patented Use:METHOD OF TREATING CHRONIC IRON OVERLOAD

Expired Orange Book Patents for NDA: 206910

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-001Mar 30, 2015► Subscribe► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-003Mar 30, 2015► Subscribe► Subscribe
Novartis Pharms CorpJADENUdeferasiroxTABLET;ORAL206910-002Mar 30, 2015► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Chinese Patent Office
McKesson
Express Scripts
McKinsey
Dow
Chubb
Cipla
Fish and Richardson
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot